Aurobindo Pharma Q2 FY27: revenue up 23.9% to ₹10,263 Cr, net profit up 32.5% to ₹1,124 Cr
Results · Finvezto · 4 Nov 2026 · Aurobindo Pharma (AUROPHARMA)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 10,263 | +12.2% | +23.9% |
| Operating profit | 2,156 | +14.6% | +28.5% |
| Net profit | 1,124 | +8.9% | +32.5% |
| Operating margin | 21.0% | +0.4 pp | +0.8 pp |
| Net margin | 10.9% | -0.3 pp | +0.7 pp |
Key points
- For Q2 FY27, Aurobindo Pharma reported consolidated revenue from operations of Rs 10,263 crore, up 23.9% year-on-year, EBITDA before forex and other income of Rs 2,156 crore, up 28.5%, and net profit of Rs 1,124 crore, up 32.5%. NSE filing
- Performance was driven by 25.2% growth in US revenue to Rs 4,555 crore and 27.5% growth in Europe revenue to Rs 3,161 crore, while an interim dividend of Rs 7.0 per share was declared. NSE filing
- Revenue was ₹10,263 Cr, up 23.9% on a year earlier and up 12.2% on the quarter before. Finvezto data
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 20.5%, 19.8%, 20.6%, 21.0%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 910, 921, 1,032, 1,124.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.